Corcept Can't Escape Teva's Mifepristone Antitrust Suit
By Lauren Berg · September 15, 2025, 7:59 PM EDT
Corcept Therapeutics must face most of Teva Pharmaceuticals' lawsuit alleging it suppressed generic competition for its brand-name medication used to treat a rare cortisol disorder, a California federal judge ruled, saying...
To view the full article, register now.